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Abstract
Background: At least four laboratories have shown that endogenous cardiac progenitor cells (CPCs) can be grown directly
from adult heart tissue in primary culture, as cardiospheres or their progeny (cardiosphere-derived cells, CDCs). Indeed,
CDCs are already being tested in a clinical trial for cardiac regeneration. Nevertheless, the validity of the cardiosphere
strategy to generate CPCs has been called into question by reports based on variant methods. In those reports,
cardiospheres are argued to be cardiomyogenic only because of retained cardiomyocytes, and stem cell activity has been
proposed to reflect hematological contamination. We use a variety of approaches (including genetic lineage tracing) to
show that neither artifact is applicable to cardiospheres and CDCs grown using established methods, and we further
document the stem cell characteristics (namely, clonogenicity and multilineage potential) of CDCs.
Methodology/Principal Findings: CPCs were expanded from human endomyocardial biopsies (n=160), adult bi-transgenic
MerCreMer-Z/EG mice (n=6), adult C57BL/6 mice (n=18), adult GFP
+ C57BL/6 transgenic mice (n=3), Yucatan mini pigs
(n=67), adult SCID beige mice (n=8), and adult Wistar-Kyoto rats (n=80). Cellular yield was enhanced by collagenase
digestion and process standardization; yield was reduced in altered media and in specific animal strains. Heparinization/
retrograde organ perfusion did not alter the ability to generate outgrowth from myocardial sample. The initial outgrowth
from myocardial samples was enriched for sub-populations of CPCs (c-Kit
+), endothelial cells (CD31
+, CD34
+), and
mesenchymal cells (CD90
+). Lineage tracing using MerCreMer-Z/EG transgenic mice revealed that the presence of
cardiomyocytes in the cellular outgrowth is not required for the generation of CPCs. Rat CDCs are shown to be clonogenic,
and cloned CDCs exhibit spontaneous multineage potential.
Conclusions/Significance: This study demonstrates that direct culture and expansion of CPCs from myocardial tissue is
simple, straightforward, and reproducible when appropriate techniques are used.
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Introduction
Congestive heart failure is a common clinical syndrome
associated with significant morbidity, mortality and health care
costs. Despite gains in other realms of cardiovascular disease, heart
failure is the only cardiovascular disease that has been increasing
in both incidence and prevalence [1]. The strategy of transplanting
stem cells into damaged myocardium is emerging as a novel
alternative in the treatment of this public health challenge. Ideal
graft cells should be non-immunogenic, easy to expand in vitro and
be able to engraft and differentiate into functional cardiac
myocytes that couple electromechanically with the surrounding
myocardium. Most importantly, transplanted graft cells should
improve cardiac function and prevent ventricular remodelling. To
date, a number of different cell types have been transplanted in
experimental models, including fetal myocytes, embryonic stem
cell derived myocytes, skeletal myoblasts, mesenchymal stem cells
and several cell types derived from the bone marrow. Most
recently, evidence that the human heart undergoes cardiomyocyte
renewal throughout life has highlighted the potential of endoge-
nous cardiac progenitor cells for cardiomyocyte replacement [2–
4].
Our lab and others have been studying and refining methods to
extract and expand CPCs directly from cardiac tissue [5–7].
Messina and colleagues first demonstrated that CPCs could be
grown directly from cardiac tissue and further enriched within
spherical aggregates, termed cardiospheres [8]. After injection into
the injured heart, cardiospheres exhibit multilineage differentia-
tion and confer functional benefits. Our group has advanced this
method towards clinical translation by expanding cells from
cardiospheres in monolayer culture, to yield cardiosphere-derived
cells (CDCs) [5]. We have demonstrated that CDCs engraft,
differentiate, secrete pro-angiogenic/cardiogenic cytokines and
improve post-myocardial infarction (MI) function/perfusion
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trials (CADUCEUS; see ClinicalTrials.gov). Other groups have
studied sub-populations within the initial outgrowth from cardiac
samples by allowing cells to proliferate from the initial cardiac
tissue and then selecting fractions for further study [10–12]. Cells
from these sub-populations have been shown to be clonogenic and
multipotent while remaining capable of self-renewal.
Several recent papers have varied the techniques used to
proliferate, enrich and expand CPCs, with discrepant results [13–
15]. On the basis of these results, the validity of the cardiosphere
method has been questioned. To clarify these important
differences and to detail our experience with this culture
technique, we outline the broad applicability of our CPC
generation method, describe the effects of culture variations on
phenotype, and use lineage tracing explore the origin of these
promising therapeutic cells. We also demonstrate that CDCs are
clonogenic, and that cloned CDCs are multipotent. Taken
together, the findings support the validity of established cardio-
sphere-based methods for the generation of CPCs.
Materials and Methods
Ethics statement
This study was conducted according to the principles
expressed inthe Declaration of Helsinki. The study was approved
by the Institutional Review Board of the Cedars-Sinai Medical
Center and by the Institutional Review Board of the Johns
Hopkins University. All patients provided written informed
consent for the collection of samples and subsequent analysis. All
animal procedures were conducted in accordance with humane
animal care standards outlined in the NIH Guide for the Care
and Use of Experimental Animals and were approved by the
Cedars-Sinai Medical Center Animal Care and Use Committee
and by the Johns Hopkins University Animal Care and Use
Committee.
Cell culture
Cardiac progenitor cells were cultured from human endomyo-
cardial biopsies, adult bi-transgenic MerCreMer-Z/EG mice
(12 weeks old; Jackson Laboratory, MA), adult C57BL/6 mice
(10 weeks old; Harlan labs, Indianapolis, IN), adult GFP
+ C57BL/
6 transgenic mice (6–7 weeks old; Jackson Laboratory), Yucatan
mini pigs (8 months old; S&S Farms, CA), adult SCID beige mice
(8–9 weeks olds; Harlan Labs) and adult Wistar-Kyoto rats (8–9
weeks old; Harlan Labs), as previously described with several
modifications [5,8].
In the case of human percutaneous endomyocardial biopsy
specimens, specimens were obtained during clinically-indicated
procedures after informed consent under a protocol approved by
the Institutional Review Board. Porcine endomyocardial speci-
mens were sampled from the right ventricular septum using the
bioptome in a similar manner. Biopsy specimens were stored on
ice in high-potassium cardioplegic solution (5% glucose, 68.6 mM
mannitol, 12.5 meq potassium chloride, 12.5 meq sodium
bicarbonate, 10 units/mL heparin) to maintain tissue viability
during transport. Tissue was processed within 2 hours.
In mice and rats, the hearts were excised with the animal under
general anesthetic and the tissue was processed immediately. In a
subset of WK rats, hearts were excised after heparinization
(1000 U IV via inferior vena cava) and underwent retrograde
perfusion with heparinized PBS to minimize thrombus formation
prior to sectioning and washing with heparinized PBS.
The myocardial specimens were then cut into fragments less
than 1 mm
3, washed and partially digested with collagenase
(MerCreMer-Z/EG mice, mini pigs, WK rats; 1 mg/ml; GIBCO,
Carlsbad, Ca) or trypsin (human endomyocardial biopsies, C57
mice, GFP+ mice and SCID mice; 0.05%; GIBCO). These tissue
fragments were culture as cardiac explants on fibronectin (20 mg/
ml; Sigma) coated dishes in cardiac explant media (CEM; Iscove’s
Modified Dulbecco’s Medium (GIBCO), fetal bovine serum (10%
(mini swine only) or 20% (all other specimens); HyClone, Logan,
UT), 100 U/ml penicillin G (GIBCO), 100 U/ml streptomycin
(GIBCO), 2 mmol/l L-glutamine (Invitrogen, Carlsbad, CA), and
0.1 mmol/l 2-mercaptoethanol (GIBCO)). A subset of WK
cardiac explants specimens were cultured in either 20% CEM or
endothelial cell growth media (EGM2, Lonza, Walkerville, MD).
After a variable period of growth, a layer of stromal-like cells
emerged from the cardiac explant over which phase bright cells
proliferated. The loosely-adherent cells surrounding the explant
(termed cardiac outgrowth) were harvested using mild enzymatic
digestion (0.05% trypsin under direct visualization or no more
than 2 minutes, GIBCO). Cardiac outgrowth could be harvested
up to four more times from the same specimen. For experiments
using CDCs, cardiac outgrowth was seeded at 2610
4 cells/ml on
poly-D-lysine coated dishes in cardiosphere growing media (CGM;
35% IMDM/65% DMEM-Ham’s F-12 (GIBCO), 2% B27
(GIBCO), 0.1 mmol/L 2-mercaptoethanol(GIBCO), 10 ng/ml
EGF(RD Systems), 20 ng/ml bFGF(PeproTech), 40 nmol/L
Cardiotrophin-1 (RD Systems), 40 nmol/L thrombin (Sigma),
100 U/ml penicillin G, 100 U/ml streptomycin, 2 mmol/l L-
glutamine). In all mini swine and a portion of the human
endomyocardial biopsy specimens, cardiospheres were cultured in
CEM with 10% FBS. Several days later, cells that remained
adherent to the poly-D-lysine coated dishes were discarded, while
detached cardiospheres were harvested, plated on fibronectin
coated flasks and cultured in CEM (10% or 20%, as indicated
above) to generate CDCs.
For single-cell cloning experiments, rat CDCs were first plated at
an assumed density of 1 cell per well in a 96-well plate coated with
fibronectin.Highly-proliferative clones wereselected forsubcloning,
and subclones were plated at a visually-verified density of 1 cell per
well. Clones were split (1:5) when they reached confluency.
Flow cytometry
Flow cytometry experiments were performed using benchtop
flow cytometers (FACSCalibur and LSRII; BD Biosciences, San
Jose, Ca). Monoclonal antibodies were labeled with fluorophores
using commercial kits as required (Molecular Probes, Eugene,
OR). The following monoclonal antibodies and conjugated
fluorochromes were used with corresponding isotype controls:
AA4 (AR32AA4, BD Pharmigen, San Jose, Ca), CD3
(MCA772FB, AbD Serotec, Oxford, UK), CD11b (MCA275FB,
AbD Serotec), CD31 (sc-28188 Santa Cruz Biotech; BD
Pharmingen 555445), CD34 (Chemicon CBL555F); CD45
(MCA340FB AbD Serotec; BD Pharmingen 555482), CD90-
FITC (Dianova DIA120); c-Kit (sc-168 Santa Cruz Biotech; BD
Pharmingen 550412), Ox-62 (MCA1029G, AbD Serotec). Fluo-
rescent compensation was performed using single labeled controls.
The percentage of positive cells was defined as the percent of the
population falling above the 99th percentile of an isotype-matched
antibody control cell population. All measures were performed
using proprietary software (Flow-Jo 7.2.2 Treestar Inc., Ashland,
OR, USA; CellQuest, BD Biosciences).
Genetic fate mapping
Bi-transgenic MerCreMer-Z/EG mice were produced by
crossbreeding cardiomyocyte-specific MerCreMer mice [16] and
Z/EG mice [17] (Jackson Laboratory) [18]. Briefly, the Z/EG
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beta-actin promoter driving floxed beta-galactosidase followed by
multiple stop codons and subsequently eGFP. Double heterozy-
gous bi-transgenic MerCreMer-Z/EG mice were used for the
myocyte lineage tracing experiments after induction of Cre
recombination for GFP labeling exclusively in cardiomyocytes by
4-OH-Tamoxifen treatment [18]. Tamoxifen-treated bi-transgen-
ic mice were used at the age of 10 week. Bi-transgenic hearts
underwent the cell culture on 2-well chamber slides with
immunostaining and microscopy performed at times indicated
after plating. Animal genotype was verified by standard PCR on
tail genomic DNA (primers available upon request).
Immunostaining and microscopy
For immunohistochemistry, explants were cultured directly on
fibronectin on 2-well chamber slides, fixed with 4% paraformal-
dehyde and stained in the whole mount. Cardiospheres were fixed
in ethanol/acetone and stained in the whole mount. Confocal
fluorescence imaging was performed on an Eclipse TE2000-U
(Nikon, Melville, NY) equipped with a krypton/argon laser using
UltraVIEW software (PerkinElmer, Boston, Mass). The following
monoclonal antibodies were used: and GFP (sc-30200, Santa Cruz
Biotech), cardiac troponin I (MAB3150,Chemicon), CD31
(550389, BD Pharmingen), CD34 (550390, BD Pharmingen),
CD45 (555482, BD Pharmingen), CD90 (550402,BD Pharmin-
gen), CD105 (MAB10971, R&D Systems), CD133 (CD133/1,
Miltenyi Biotec), c-Kit (sc-168, Santa Cruz Biotech), connexin 43
(MAB3067, Chemicon), desmin (ab6322, Abcam), Ki67 (ab833,
Abcam), MDR1 (MAB4334, Chemicon), myosin heavy chain
(Rome, Italy10), Nkx2.5 (sc-14033, Santa Cruz), procollagen type
I (MAB1912, Chemicon) and vimentin (AB1620, Chemicon).
Secondary antibodies conjugated with Alexa fluorochromes were
used.
Statistical analysis
All data is presented as mean 6 SEM. To determine if
differences existed within groups, data was analyzed by a one-way
ANOVA; if such differences existed, Bonferroni’s corrected t-test
was used to determine the group(s) with the difference(s) (G-B Stat
software). A final value of P#0.05 was considered significant for all
analyses. All probability values reported are 2-sided.
Results
Cardiac progenitor cells can be reliably grown from
myocardial tissue
We sectioned, enzymatically digested and plated myocardial
tissue from human endomyocardial biopsies (n=160), adult bi-
transgenic MerCreMer-Z/EG mice (n=6), adult C57 mice
(n=18), adult GFP
+ C57BL/6 transgenic mice (n=3), Yucatan
mini pigs (n=67), adult SCID mice (n=8) and adult Wistar-
Kyoto rats (n=80). Human ventricular biopsy specimens
(21.0615.9 mg) were obtained from patients who had undergone
heart transplant (n=59; 75% of recipients male (52614 yo); 67%
of donors male (32612 yo)) or with unexplained cardiomyopathy
(n=12; 67% male; 49615 yo).
After several days in culture, a layer of stromal-like cells arose
from adherent plated tissue (termed cardiac explants) over which
small, round, phase-bright cells migrated. This surrounding layer of
‘‘outgrowth’’ cells became confluent within 762 days of plating
mouse, pig and rat tissue, whereas human tissue typically became
confluent 1761 days after plating. As shown in Figure 1A, the gross
histological appearance of the outgrowth from the plated tissue of
different species was morphologically similar. Interestingly, we
noted variable success proliferating outgrowth using specific strains
of mice, particularly the C57BL/6 WT mice (Harlan) with typically
only 20% successfully forming outgrowth. This difficulty was not
Figure 1. Culture cardiac explants. (A) Typical phase image examples of the spontaneous outgrowth from plated human, mouse, pig and rat
tissue. (B) Serial imaging of MerCreMer-Z/EG mouse tissue cardiac explant tissue demonstrating the gradual rounding of margins and incorporation
into the flattened outgrowth.
doi:10.1371/journal.pone.0007195.g001
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+ C57BL/6
or MerCreMer-Z/EG) originally derived from the C57 strain.
Cardiac progenitor cells are not of hematological origin
Given concerns that cardiac outgrowth may represent prolifer-
ation of retained hematological components [13], a subset of WK
rats (n=45) was heparinized prior to organ harvest. These hearts
were then extracted and underwent retrograde perfusion with
heparinized saline prior to sectioning and further washing. In all
animals, we noted that outgrowth reliably grew in culture
following organ perfusion and serial explant washing with heparin.
This observation refutes the notion that outgrowth production is
dependent upon the presence of retained circulatory elements.
Once confluent, the outgrowth cells surrounding the explant
were collected 3 times after the initial harvest using mild enzymatic
digestion. As the plated explant tissues persisted in culture, they
became progressively more rounded with less-defined margins
(Figure 1B). Flow cytometry demonstrated that the initial
outgrowth collected from human and rat tissue is enriched for
sub-populations that antigenically resemble CPCs (c-Kit
+), endo-
thelial cells (CD31
+, CD34
+) and mesenchymal cells (CD90
+). As
shown in Figure 2A, the proportion of c-Kit
+, CD31
+, CD34
+ and
CD90
+ cells falling above the 99th percentile of the control was
not significantly different between human and rats. Importantly,
these collections where negative for markers of hematological
origin (hematological lineage screen), including AA4 (mast cell
antigen; Figure 2B) and CD45 (leukocyte common antigen;
Figure 2C). This finding indicates that hematological contamina-
tion does not constitute a major component of ex-vivo expanded
CPCs.
Variations in culture conditions alter culture efficiency
and phenotype
To enhance the efficiency of CPC generation, we examined the
influence of different culture conditions on culture output. While
difficult to quantify, we have noted that mincing tissue more finely
reliably enhances the generation of outgrowth and the eventual
yield of collected cells. Initial digestion of the minced tissue also
plays an important role in the amount of time required for
outgrowth to attain confluence. The substitution of collagenase for
trypsin significantlyreduced theamountoftime required for human
cells to attain initial confluence (17.360.7 days vs. 22.161.5,
respectively; p,0.01) and significantly increased outgrowth yields
(7.7E+0569.9E+04 vs. 8.7E+0461.3E+04, respectively; p,0.01).
In contrast, alteration of the media from standard CEM to
endothelial media markedly reduced both the yield
(1.7E+0661.1E+06 vs. 3.3E+0563.1E+05; p,0.01) and the
CPC content (c-Kit+ cells 1567% vs. 361%, p,0.01) of the
collected aggregate (Figure 3A). We noted that decreasing the FBS
content of CEM from 20% to 10% reduced the proportion of
CDCs expressing CD34 (7.561.2 vs. 0.960.7, respectively;
p,0.01), but did not alter the other subpopulations within the
human flow cytometry profile (Figure 3B).
A portion of CPCs arise from myocardial de-
differentiation
To explore the ultimate origin of CPCs within outgrowth, we
used a bi-transgenic MerCreMer-Z/EG mouse model with
cardiomyocytes irreversibly GFP-labeled after Tamoxifen treat-
ment (Figure 4A). As shown in Figure 4B and 4C, the outgrowth
from plated tissue is established 5 days after plating with no
detectable GFP fluorescence. Aggregate data were collected from
.7 random fields to quantify the composition of cells in the initial
outgrowth from myocardial samples. These data showed that
6.460.5% of the cells counted were c-kit
+ but GFP
2; such CPCs
cannot have been of cardiomyocyte origin. Thus, cardiomyocytes
are not present in the early outgrowth, and an appreciable fraction
of the outgrowth cells are CPCs of non-cardiomyocyte origin. The
contention that ‘‘contaminating myocardial tissue fragments’’ in
the outgrowth are important is therefore rejected [14].
Adult human cardiospheres exhibit a complex mixed cell
phenotype
As shown above, the direct outgrowth from cardiac samples
contains a mixed cell population of CPCs (c-Kit
+), endothelial cells
(CD31
+, CD34
+) and mesenchymal cells (CD90
+). To explore the
effects of three dimensional sphere culture on these sub-
populations, we examined human cardiospheres for expression
of CPC-related proteins (c-Kit, MDR1), mesenchymal-related
proteins (CD105, CD90, procollagen type I, vimentin), endothe-
lial-related proteins (CD105, CD133, CD31, CD34), hematopoi-
etic-related proteins (CD34, CD45), cardiomyocyte-related pro-
teins (Cx43, cMHC, cTnI, Nkx2.5 and desmin), and Ki67 to
identify proliferative cells. As shown in Figure 5, cardiospheres
consist of distinct layers with expression of the CPC marker c-Kit
in the core (Figure 5A) and the mesenchymal marker CD105 on
their periphery (Figure 5D). During cardiosphere culture,
proliferative cells (Ki67 positive) were found primarily in the core
of the sphere (Figure 5P). Many cardiospheres manifest cardio-
myocyte-specific sarcomeric proteins (aMHC, cTnI) in the
peripheral cells, indicative of partial myogenic differentiation
(Figure 5J and 5K). On their periphery, cardiospheres also
expressed CD31 (Figure 5C), CD133 (Figure 5O) and MDR-1
(Figure 5B). In their core, cardiospheres also often expressed
Figure 2. Flow cytometric analysis of the first outgrowth
collection from cardiac tissue. (A) A comparison of the proportion
of the initial human and WK rat outgrowth cells expressing markers of
CPC (c-Kit), endothelial (CD31, CD34) and mesenchymal (CD90) origin.
(B) Flow cytometry dot plot of the initial cellular outgrowth harvested
from WK rat tissue demonstrating co-segregation of mast cell antigen
AA4 with CPC marker c-Kit. (C) Flow cytometry dot plots of the initial
outgrowth harvested from WK rat tissue demonstrating the co-
segregation and abundance of c-Kit and CD45.
doi:10.1371/journal.pone.0007195.g002
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(Figure 5M). Only rarely was MDR-1 expressed in the core of
human cardiospheres (,5%, not shown). Cardiospheres were
consistently negative for CD34 (Figure 5D) and CD45 (Figure 5N).
We conclude that core cells have a cardiac progenitor immuno-
phenotype dominated by the expression of stem cell and
cardiomyocyte-related antigens. Peripheral cells represent sponta-
neous differentiation of precursor cells into endothelial, mesen-
chymal, or cardiomyogenic lineages, and/or the encapsulation of
core progenitors by a subset of supportive cardiac mesenchymal
cells. Thus, when CPCs are cultured directly from myocardial
tissue by carefully-established methods, further sub-culture permits
the formation of self-organizing cardiospheres that create a
complex, niche-like environment favoring the proliferation of
cardiac progenitors in their core and a surface phenotype marked
by mesenchymal- and cardiac-specific antigens [19,20].
Figure 3. Effect of variation in culture methods on phenotype. (A) Effect of FBS content the proportion of the human CDCs expressing
markers of CPC (c-Kit), endothelial (CD31, CD34) and mesenchymal (CD90) origin. (B) Flow cytometry dot plot demonstrating the influence of
endothelial media and standard cardiac explant media on the proportion of WK rat outgrowth cells expressing the CPC marker c-Kit.
doi:10.1371/journal.pone.0007195.g003
Figure 4. Lineage tracing of outgrowth from cardiac samples. (A) RT PCR depicting recombination following administration of tamoxifen. (B)
Phase and fluorescent imaging of the outgrowth from MerCreMer-Z/EG mouse tissue 0 and 5 days after plating. (C) Immunohistochemistry depicting
myocytes and non-myocyte derived c-kit
+ cells after 2 weeks in culture. Inset lines highlight c-kit
+ and GFP- cells.
doi:10.1371/journal.pone.0007195.g004
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renewal
CDCs, derived from rat specimens, readily formed clones
when plated as single cells (Figur e6 ) .N i n ec l o n a lc e l ll i n e sw e r e
developed (from an initial 65 visually-verified single cells) which
had an average doubling time of 42.260.7 hours during the first
month. Clones proliferated for one month before proliferation
spontaneously slowed and morphological changes occurred in
most cells. After two months in culture (and 17.661.8 population
doublings), clonal CDC populations exhibited spontaneous
phenotypic heterogeneity. A small fraction of c-Kit expressing
cells (4.9% by flow cytometry) could be seen dividing among still-
proliferative groups of cells; other cells expressed cardiac
troponin I (cTnI), a-smooth muscle actin (a-SMA), or von
Willebrand factor (vWf), indicative of multipotentiality with a
propensity to myocyte, smooth muscle, and endothelial lineages
in vitro. These findings, as well as those with cardiosphere
immunostaining (Figure 5 and related text above), are inconsis-
tent with the sweeping claim that cardiosphere cells are
fibroblasts lacking cardiomyogenic or endothelial differentiation
potential [14].
Discussion
This study demonstrates the broad applicability of techniques
used to culture and expand CPCs from myocardial tissue. We
have shown that CPCs can be grown from human, pig, mouse and
rat tissue with very little identity deviation in CPC, endothelial and
mesenchymal subpopulations. These data provide strong support
for the concept that endogenous CPCs can be successfully grown
for autologous cellular cardiomyoplasty [5,8,10–12,15]. The
clinical utility of CDC technology remains conjectural, but a
phase 1 clinical trial with intra-coronary administration of
autologous CDCs has begun, with evaluation of safety as the
initial goal (CADUCEUS; see ClinicalTrials.gov).
Recent studies have confirmed our observation that technical
deviance transforms the culture phenotype [13]. Shenje et al.
demonstrated that culture with altered media following retrograde
perfusion inconsistently provides outgrowth. These investigators
attribute this finding to the purging of retained hematological cells
responsible for generating outgrowth, as their limited series (n=4)
clustered culture failures in the retrograde perfusion group. Our
series of successful cultures with retrograde perfusion (n=45) in
the absence of hematological cells (CD45
2, lin
2) disproves the
Figure 5. Immunophenotyping of cardiospheres. Widefield images of representative cardiospheres immunostained for 16 different cardiac-
related antigens.
doi:10.1371/journal.pone.0007195.g005
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generation of CPCs from cardiac biopsies. The findings of Shenje
et al. may reflect non-random clustering, as C57 WT mice
inconsistently proliferate outgrowth, and retrograde perfusion has
negligible effects on the generation of outgrowth from myocardial
samples.
In a separate study, Andersen and colleagues grew cardio-
spheres from neonatal WK rats using unconventional methods
[14]. Although critical of the literature, Andersen et al. did not
attempt to reproduce published methods for the preparation of
cardiospheres. Instead, the authors used a novel source tissue
(neonatal rat heart); they stored the tissue in an untested solution;
they added a filtering step which is not part of published protocols;
and, they used harsh enzymatic detachment to collect cells from
explant culture (5 min of trypsin treatment). These investigators
found that neonatal WK rat cardiospheres contain a significant
population of hematopoietic progenitors (as indicated by CD45).
Of note, Andersen et al. ’s non-hematological cells (CD45-) consist
overwhelmingly of cardiac fibroblasts, as evidenced by the
presence of collagen I. This result is likely due to one or more of
the technical variations which they introduced. Andersen et al.
further attributed the sparse cardiomyogenic activity they
observed to contamination by myocardial fragments that could
be removed by filtering the outgrowth. Our studies using
myocardial lineage tracing debunk the importance of the
postulated myocyte contamination, as we demonstrate that the
presence of cardiomyocytes in the cellular outgrowth is not
required for the generation of CPCs. We do not question the
possibility that product filtration after prolonged enzymatic
treatment may enrich in fibroblasts while selecting against genuine
CPCs. Andersen et al. did not use human tissue, nor did they
attempt to reproduce published successful protocols for isolating
cardiac stem cells from animal or human tissue. Accordingly, their
work provides no justification for the indictment of the clinical
utility of cardiospheres.
In conclusion, we have demonstrated that, using established
methods, expansion and proliferation of CPCs is simple and
straightforward. This study has also shown that subtle variations in
technique markedly alter phenotype and severely limit compar-
isons that can be made using variant methods. Finally, genetic
lineage tracing has demonstrated that a portion of CPCs arise
from myocardial dedifferentiation with the remainder originating
proliferation of endogenous progenitors.
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Figure 6. CDCs are self-renewing, clonogenic, and multipotent. (A) Phase image of a single plated rat CDC (Day 0) demonstrating
proliferation (Day 27) and spontaneous morphological changes (Day 48). (B) Proliferation of nine clonal cell lines. (C) Differentiation of clonogenic
cells into endothelial precursors (vWF), myocyte precursors(cTNI) and smooth muscle precursors (a-SMA). Also shown are clusters of cardiac
progenitors (c-Kit) that persist during long-term culture.
doi:10.1371/journal.pone.0007195.g006
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